These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26075314)

  • 1. Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells.
    El-Mashtoly SF; Yosef HK; Petersen D; Mavarani L; Maghnouj A; Hahn S; Kötting C; Gerwert K
    Anal Chem; 2015 Jul; 87(14):7297-304. PubMed ID: 26075314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
    Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
    Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.
    Yosef HK; Mavarani L; Maghnouj A; Hahn S; El-Mashtoly SF; Gerwert K
    Anal Bioanal Chem; 2015 Nov; 407(27):8321-31. PubMed ID: 26168967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.
    Kasper S; Breitenbuecher F; Reis H; Brandau S; Worm K; Köhler J; Paul A; Trarbach T; Schmid KW; Schuler M
    Oncogene; 2013 Jun; 32(23):2873-81. PubMed ID: 22797062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy.
    Yosef HK; Frick T; Hammoud MK; Maghnouj A; Hahn S; Gerwert K; El-Mashtoly SF
    Analyst; 2018 Dec; 143(24):6069-6078. PubMed ID: 30426981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
    Dempke WC; Heinemann V
    Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
    Freeman DJ; Juan T; Reiner M; Hecht JR; Meropol NJ; Berlin J; Mitchell E; Sarosi I; Radinsky R; Amado RG
    Clin Colorectal Cancer; 2008 May; 7(3):184-90. PubMed ID: 18621636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy: novel action of panitumumab in colon cancer.
    Giannopoulou E; Antonacopoulou A; Matsouka P; Kalofonos HP
    Anticancer Res; 2009 Dec; 29(12):5077-82. PubMed ID: 20044619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
    Baynes RD; Gansert J
    Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Personalized medicine--the future is already here].
    Abadi-Korek I; Shemer J
    Harefuah; 2011 May; 150(5):451-2, 490. PubMed ID: 21678641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
    Zhang W; Stabile LP; Keohavong P; Romkes M; Grandis JR; Traynor AM; Siegfried JM
    J Thorac Oncol; 2006 Sep; 1(7):635-47. PubMed ID: 17409930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.
    Toulany M; Kasten-Pisula U; Brammer I; Wang S; Chen J; Dittmann K; Baumann M; Dikomey E; Rodemann HP
    Clin Cancer Res; 2006 Jul; 12(13):4119-26. PubMed ID: 16818713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.
    Jiang Y; Mackley H; Cheng H; Ajani JA
    Biomark Med; 2010 Aug; 4(4):535-41. PubMed ID: 20701442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.